An Unconventional Biotech

/ SARS-CoV-2

Challenge

Our collective surprise at the failure of Big Pharma and Systemic Healthcare to protect us from a pandemic they had spent decades preparing for, has catalyzed us to create a new approach. It’s a path that empowers us to discover Nature-Tech best answers that sidestep regulatory barriers to access

/ SARS-CoV-2

Challenge

It has been estimated that approximately eighty percent of SARS CoV2 infections result from nasal inhaled viral particles. Nasal administration of SARS CoV2 neutralizing antibodies could provide temporary protection against SARS-CoV-2 infections. Even after vaccination, individuals with immunity can be asymptomatic spreaders.

/ Alzheimer's

Challenge

Alzheimer's Disease (AD) is the most common cause of age-related dementia associated with progressive memory loss and cognitive function. It is characterized by neuroinflammation and oxidative stress leading to neurofibrillary tangles (caused by intracellular accumulation of hyperphosphorylated TAU proteins) and extracellular deposition of B amyloid (Ab) peptide deposition.

Despite the availability of several medications, none have proven to either reverse or stop the progression of this disease. Exosomes are microvesicles 30-100nm in diameter and act as cargos of inflammatory molecules and induce neuroinflammation by exchange of information between neurons and glia and initiate an inflammatory cascade.

/ Diabetes

Challenge

Diabetes is a global disease that affects hundreds of millions across the world. It is the leading cause of blindness and amputation and continues to rise each year. Islet damage of the pancreas through unregulated blood sugar control is the fundamental cause and ultimate result of diabetes. Now after the development of the Edmonton Protocol the Diomics research team has: